Cargando…

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?

Immune checkpoint inhibitors (ICI) have been used as immunotherapy for hepatocellular carcinoma (HCC) with promising but still limited results. Identification of immune elements in the tumor microenvironment of individual HCC patients may help to understand the correlations of responses, as well as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Repáraz, David, Aparicio, Belén, Llopiz, Diana, Hervás-Stubbs, Sandra, Sarobe, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875127/ https://www.ncbi.nlm.nih.gov/pubmed/35216137 http://dx.doi.org/10.3390/ijms23042022

Ejemplares similares

Neoantigens as potential vaccines in hepatocellular carcinoma
por: Repáraz, David, et al.
Publicado: (2022)

Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
por: Aparicio, Belén, et al.
Publicado: (2022)

Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination
por: Repáraz, David, et al.
Publicado: (2022)

Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma
por: Silva, Leyre, et al.
Publicado: (2020)

IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination
por: Llopiz, Diana, et al.
Publicado: (2016)

Advances in immunotherapy for hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2021)

Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10
por: Llopiz, Diana, et al.
Publicado: (2018)

Mutated trimeric RBD vaccines: a platform against variants of concern
por: Aparicio, Belén, et al.
Publicado: (2023)

Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor
por: Lozano, Teresa, et al.
Publicado: (2017)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
por: Chen, Pu, et al.
Publicado: (2021)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors
por: Wang, Wenwen, et al.
Publicado: (2022)

Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
por: Pao, Shih-Cheng, et al.
Publicado: (2022)

Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
por: Aparicio, Belén, et al.
Publicado: (2021)

The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
por: Hsu, Hsiao-Mei, et al.
Publicado: (2023)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
por: Huemer, Florian, et al.
Publicado: (2021)

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
por: Shen, Luhui, et al.
Publicado: (2023)

NeoFox: annotating neoantigen candidates with neoantigen features
por: Lang, Franziska, et al.
Publicado: (2021)

Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy
por: Navarro, Flor, et al.
Publicado: (2022)

Helper cell-independent antitumor activity of potent CD8(+) T cell epitope peptide vaccines is dependent upon CD40L
por: Llopiz, Diana, et al.
Publicado: (2013)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
por: Karaki, Soumaya, et al.
Publicado: (2016)

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
por: Wirth, Thomas C., et al.
Publicado: (2017)

Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
por: Wu, Ming, et al.
Publicado: (2023)

Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
por: Li, Shamin, et al.
Publicado: (2021)

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
por: Anzar, Irantzu, et al.
Publicado: (2023)

The Abscopal Effect in the Era of Checkpoint Inhibitors
por: Kodet, Ondřej, et al.
Publicado: (2021)

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
por: Blass, Eryn, et al.
Publicado: (2021)

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies
por: Reynolds, Carson R., et al.
Publicado: (2022)

Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection
por: Zabaleta, Aintzane, et al.
Publicado: (2015)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
por: D’Alise, Anna Morena, et al.
Publicado: (2019)

The perfect personalized cancer therapy: cancer vaccines against neoantigens
por: Aurisicchio, Luigi, et al.
Publicado: (2018)

Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan
por: Taketomi, Akinobu
Publicado: (2021)

Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors
por: Clark, Curtis A., et al.
Publicado: (2022)

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens
por: Arribillaga, Laura, et al.
Publicado: (2020)

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
por: Löffler, Markus W., et al.
Publicado: (2019)

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021)

Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
por: Cai, Zhixiong, et al.
Publicado: (2021)

Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
por: Lang, Franziska, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qs6vrgaevesnoalatqunrr5kkv